Switzerland

F. Hoffmann-La Roche

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Switzerland

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Roche Reports Additional Safety Data of Satralizumab in NMOSD

Lead Product(s): Satralizumab

Therapeutic Area: Neurology Product Name: Undisclosed

Highest Development Status: Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 22, 2020

Details:

Pooled data from two pivotal Phase III open-label extension (OLE) studies show satralizumab was well-tolerated as a monotherapy or in combination with baseline immunosuppressive therapy in people with neuromyelitis optica spectrum disorder (NMOSD).

Arvelle Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Switzerland

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Arvelle Therapeutics Announces Results of a Randomised Study Showing that Adjunctive Cenobamate Significantly Improved Seizure

Lead Product(s): Cenobamate

Therapeutic Area: Neurology Product Name: Undisclosed

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 21, 2020

Details:

28% of patients receiving cenobamate achieved seizure-freedom (zero seizures) during the study’s maintenance phase, versus 9% receiving placebo1.

F. Hoffmann-La Roche

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Switzerland

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Roche Trial of Ionis Huntington’s Disease Drug Halted After Side Effects

Lead Product(s): Onis-Httrx

Therapeutic Area: Neurology Product Name: Undisclosed

Highest Development Status: Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 06, 2020

Details:

Cause of the suspension of enrollment was the occurrence of two intrathecal catheter-related infections that weren’t related to the drug.

Find

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Product Type

Companies

F. Hoffmann-La Roche

Roche Reports Additional Safety Data of Satralizumab in NMOSD

Arvelle Therapeutics

Arvelle Therapeutics Announces Results of a Randomised Study Showing that Adjunctive Cenobamate Significantly Improved Seizure

F. Hoffmann-La Roche

Roche Trial of Ionis Huntington’s Disease Drug Halted After Side Effects